enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Ruxolitinib - Wikipedia

    en.wikipedia.org/wiki/Ruxolitinib

    Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...

  3. Journal of Family Nursing - Wikipedia

    en.wikipedia.org/wiki/Journal_of_Family_Nursing

    The Journal of Family Nursing is a quarterly peer-reviewed medical journal covering the field of family ... the journal has a 2017 impact factor of 1.955. [1] References

  4. JakafiĀ® (ruxolitinib) Prescribing Information Updated with ...

    www.aol.com/news/2013-06-12-jakafi-ruxolitinib...

    The prescribing information for Jakafi now includes a new recommended starting dose of 5 mg twice daily of Jakafi for patients with baseline platelet counts between 50-100 x 10 9 /L (50,000 to ...

  5. Primary myelofibrosis - Wikipedia

    en.wikipedia.org/wiki/Primary_myelofibrosis

    In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of ...

  6. List of medical journals - Wikipedia

    en.wikipedia.org/wiki/List_of_medical_journals

    Mount Sinai Journal of Medicine: Medicine: John Wiley & Sons: English: 1934–2012 Movement Disorders: Neurology: Wiley-Liss: English: 1986–present Myanmar Medical Journal: Medicine: Myanmar Medical Association: English: 1953–present Nano Biomedicine and Engineering: Medicine: Open-Access House of Science and Technology: English: 2009–present

  7. FDA approves Incyte's treatment for chronic graft-versus-host ...

    www.aol.com/news/fda-approves-incytes-treatment...

    Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...

  8. Impact factor - Wikipedia

    en.wikipedia.org/wiki/Impact_factor

    The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly mean number of citations of articles published in the last two years in a given journal, as indexed by Clarivate's Web of Science.

  9. Research in Nursing & Health - Wikipedia

    en.wikipedia.org/wiki/Research_in_Nursing_&_Health

    Research in Nursing & Health is a peer-reviewed nursing journal covering a wide range of research that will inform ... the journal has a 2017 impact factor of 1.762 ...